适应症-话题@MedSci

#适应症#

219篇内容 | 3031人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1336742, encodeId=72291336e428e, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=拜耳瑞戈非尼转移性结直肠癌和胃肠道间质瘤双适应症国内获批, objectType=article, longId=93310, objectId=b1f1933107e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1f1933107e, replyNumber=0, likeNumber=65, createdTime=2017-03-26, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1f1933107e, moduleTitle=拜耳瑞戈非尼转移性结直肠癌和胃肠道间质瘤双适应症国内获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1f1933107e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336741, encodeId=a6d81336e41dd, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=详解2016年FDA批准的20款创新药（名称、活性成分、适应症……）, objectType=article, longId=88584, objectId=c55f8858423, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c55f8858423, replyNumber=0, likeNumber=70, createdTime=2017-02-12, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c55f8858423, moduleTitle=详解2016年FDA批准的20款创新药（名称、活性成分、适应症……）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c55f8858423)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336740, encodeId=cc341336e4016, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=第5个适应症！罗氏眼科药物Lucentis（雷珠单抗）获美国FDA批准治疗近视性脉络膜新生血管（mCNV）, objectType=article, longId=86943, objectId=563e86943ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=563e86943ab, replyNumber=0, likeNumber=55, createdTime=2017-01-09, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=563e86943ab, moduleTitle=第5个适应症！罗氏眼科药物Lucentis（雷珠单抗）获美国FDA批准治疗近视性脉络膜新生血管（mCNV）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=563e86943ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336739, encodeId=d9e81336e39fe, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=2016 RCP指南：英国PET-CT检查的适应症, objectType=article, longId=86897, objectId=4ddb8689e95, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ddb8689e95, replyNumber=0, likeNumber=29, createdTime=2017-01-08, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ddb8689e95, moduleTitle=2016 RCP指南：英国PET-CT检查的适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ddb8689e95)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336738, encodeId=3c961336e3828, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=Nature：详解FDA批准的45款肿瘤靶向药物（名称、适应症、靶点、副反应、价格&注意事项）, objectType=article, longId=86237, objectId=aab18623e66, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aab18623e66, replyNumber=0, likeNumber=55, createdTime=2017-01-01, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aab18623e66, moduleTitle=Nature：详解FDA批准的45款肿瘤靶向药物（名称、适应症、靶点、副反应、价格&注意事项）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aab18623e66)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336737, encodeId=c1821336e3722, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=FDA批准Shire血友病药物新增加适应症, objectType=article, longId=86134, objectId=f8d8861340e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8d8861340e, replyNumber=0, likeNumber=63, createdTime=2017-01-01, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8d8861340e, moduleTitle=FDA批准Shire血友病药物新增加适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8d8861340e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336736, encodeId=96c61336e3662, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=美敦力SOLITAIRE(TM)取栓支架获美国FDA许可扩大其适应症, objectType=article, longId=85754, objectId=c3f085e5450, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3f085e5450, replyNumber=0, likeNumber=74, createdTime=2016-12-29, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3f085e5450, moduleTitle=美敦力SOLITAIRE(TM)取栓支架获美国FDA许可扩大其适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3f085e5450)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336735, encodeId=cbf91336e3599, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=详解2016年FDA批准的20款创新药（名称、活性成分、适应症……）, objectType=article, longId=84803, objectId=0e798480319, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e798480319, replyNumber=0, likeNumber=76, createdTime=2016-12-22, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e798480319, moduleTitle=详解2016年FDA批准的20款创新药（名称、活性成分、适应症……）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e798480319)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336734, encodeId=30381336e34d1, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=Stroke：早期再发卒中再次溶栓的适应症研究, objectType=article, longId=81355, objectId=c0b68135561, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0b68135561, replyNumber=0, likeNumber=69, createdTime=2016-10-31, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0b68135561, moduleTitle=Stroke：早期再发卒中再次溶栓的适应症研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0b68135561)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336733, encodeId=73391336e339a, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=重磅！第一个PD－L1抑制剂获得转移期NSCLC适应症, objectType=article, longId=80506, objectId=016d805060a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=016d805060a, replyNumber=0, likeNumber=71, createdTime=2016-10-22, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=016d805060a, moduleTitle=重磅！第一个PD－L1抑制剂获得转移期NSCLC适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=016d805060a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336732, encodeId=9fce1336e32d8, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=第4个适应症！大冢抗精神病药物Abilify(阿立哌唑)获日本批准治疗儿童自闭症谱系障碍, objectType=article, longId=79540, objectId=838be95405a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=838be95405a, replyNumber=0, likeNumber=63, createdTime=2016-10-10, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=838be95405a, moduleTitle=第4个适应症！大冢抗精神病药物Abilify(阿立哌唑)获日本批准治疗儿童自闭症谱系障碍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=838be95405a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336731, encodeId=b2b61336e3177, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=重磅！FDA一次性批准诺华抗炎药Ilaris 3个新的适应症, objectType=article, longId=79021, objectId=679ce902173, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=679ce902173, replyNumber=0, likeNumber=91, createdTime=2016-10-01, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=679ce902173, moduleTitle=重磅！FDA一次性批准诺华抗炎药Ilaris 3个新的适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=679ce902173)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336730, encodeId=6c0a1336e3092, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=福音！欧盟扩大诺和诺德糖尿病鸡尾酒疗法Xultophy适应症，用于中度肾损伤, objectType=article, longId=77045, objectId=4efce704523, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4efce704523, replyNumber=0, likeNumber=79, createdTime=2016-09-10, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4efce704523, moduleTitle=福音！欧盟扩大诺和诺德糖尿病鸡尾酒疗法Xultophy适应症，用于中度肾损伤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4efce704523)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336729, encodeId=3b151336e2924, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=2016ESA立场声明——男性性功能减退症的评估和睾酮治疗的适应症发布, objectType=article, longId=76723, objectId=4bdde672350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4bdde672350, replyNumber=0, likeNumber=25, createdTime=2016-09-07, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4bdde672350, moduleTitle=2016ESA立场声明——男性性功能减退症的评估和睾酮治疗的适应症发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4bdde672350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336728, encodeId=06171336e2811, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=第4个适应症！诺华抗癌药Arzerra获FDA批准治疗复发性慢性淋巴细胞白血病（CLL）, objectType=article, longId=76568, objectId=80e0e6568b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80e0e6568b4, replyNumber=0, likeNumber=61, createdTime=2016-09-04, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80e0e6568b4, moduleTitle=第4个适应症！诺华抗癌药Arzerra获FDA批准治疗复发性慢性淋巴细胞白血病（CLL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80e0e6568b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336727, encodeId=7b8b1336e2733, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=2016ASNC/SNMMI联合政策声明——心肌灌注PET检查的临床适应症发布, objectType=article, longId=75691, objectId=3072e56917e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3072e56917e, replyNumber=0, likeNumber=65, createdTime=2016-08-25, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3072e56917e, moduleTitle=2016ASNC/SNMMI联合政策声明——心肌灌注PET检查的临床适应症发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3072e56917e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336726, encodeId=78f01336e2619, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=强生为Darzalex申请新适应症，进军多发性骨髓瘤二线治疗, objectType=article, longId=75557, objectId=f64ae5557dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f64ae5557dd, replyNumber=0, likeNumber=51, createdTime=2016-08-22, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f64ae5557dd, moduleTitle=强生为Darzalex申请新适应症，进军多发性骨髓瘤二线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f64ae5557dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336725, encodeId=23e11336e2561, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=第6个适应症！欧盟批准强生重磅抗炎药Simponi治疗多关节型幼年特发性关节炎（pJIA）, objectType=article, longId=72017, objectId=9ab1e20172f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ab1e20172f, replyNumber=0, likeNumber=68, createdTime=2016-07-05, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ab1e20172f, moduleTitle=第6个适应症！欧盟批准强生重磅抗炎药Simponi治疗多关节型幼年特发性关节炎（pJIA）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ab1e20172f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336724, encodeId=433b1336e2446, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=Stroke：缺血性卒中血管内治疗适应症的预测因子, objectType=article, longId=71932, objectId=dd46e1932b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd46e1932b2, replyNumber=0, likeNumber=51, createdTime=2016-07-02, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd46e1932b2, moduleTitle=Stroke：缺血性卒中血管内治疗适应症的预测因子, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd46e1932b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336723, encodeId=d23a1336e2364, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=喜讯！默沙东PD-1免疫疗法Keytruda治疗晚期非小细胞肺癌（NSCLC）新适应症获CHMP支持批准, objectType=article, longId=71750, objectId=6a53e17507d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a53e17507d, replyNumber=0, likeNumber=72, createdTime=2016-06-30, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a53e17507d, moduleTitle=喜讯！默沙东PD-1免疫疗法Keytruda治疗晚期非小细胞肺癌（NSCLC）新适应症获CHMP支持批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a53e17507d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

适应症

2020-05-29

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

拜耳瑞戈非尼转移性结直肠癌和胃肠道间质瘤双适应症国内获批

2017-03-26

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

详解2016年FDA批准的20款创新药（名称、活性成分、适应症……）

2017-02-12

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

第5个适应症！罗氏眼科药物Lucentis（雷珠单抗）获美国FDA批准治疗近视性脉络膜新生血管（mCNV）

2017-01-09

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

2016 RCP指南：英国PET-CT检查的适应症

2017-01-08

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

Nature：详解FDA批准的45款肿瘤靶向药物（名称、适应症、靶点、副反应、价格&注意事项）

2017-01-01

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

FDA批准Shire血友病药物新增加适应症

2017-01-01

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

美敦力SOLITAIRE(TM)取栓支架获美国FDA许可扩大其适应症

2016-12-29

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

详解2016年FDA批准的20款创新药（名称、活性成分、适应症……）

2016-12-22

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

Stroke：早期再发卒中再次溶栓的适应症研究

2016-10-31

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

重磅！第一个PD－L1抑制剂获得转移期NSCLC适应症

2016-10-22

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

第4个适应症！大冢抗精神病药物Abilify(阿立哌唑)获日本批准治疗儿童自闭症谱系障碍

2016-10-10

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

重磅！FDA一次性批准诺华抗炎药Ilaris 3个新的适应症

2016-10-01

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

福音！欧盟扩大诺和诺德糖尿病鸡尾酒疗法Xultophy适应症，用于中度肾损伤

2016-09-10

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

2016ESA立场声明——男性性功能减退症的评估和睾酮治疗的适应症发布

2016-09-07

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

第4个适应症！诺华抗癌药Arzerra获FDA批准治疗复发性慢性淋巴细胞白血病（CLL）

2016-09-04

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

2016ASNC/SNMMI联合政策声明——心肌灌注PET检查的临床适应症发布

2016-08-25

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

强生为Darzalex申请新适应症，进军多发性骨髓瘤二线治疗

2016-08-22

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

第6个适应症！欧盟批准强生重磅抗炎药Simponi治疗多关节型幼年特发性关节炎（pJIA）

2016-07-05

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

Stroke：缺血性卒中血管内治疗适应症的预测因子

2016-07-02

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

喜讯！默沙东PD-1免疫疗法Keytruda治疗晚期非小细胞肺癌（NSCLC）新适应症获CHMP支持批准

2016-06-30

科室
- - 订阅+
  - 更多科室
工具
服务